The Shiley-Marcos Alzheimer’s Disease Research Center has a wide variety of opportunities for volunteers to participate in important research studies designed to discover ways to prevent, treat, and ultimately eradicate Alzheimer’s disease. We are recruiting diverse volunteers on an ongoing basis to learn more about memory and aging.
Are you interested in participating in a research study but don't currently see one that suits you? You can now join our Research Registry to be placed on a list for future studies.
*Call the ADRC 858-822-4800 and ask for Christina Gigliotti, Ph.D. for more information on being added to the registry or to determine your eligibilty for any of our enrolling studies.
CIRM: California Institute of Regenerative Medicine
PI: Douglas Galasko, MD Contact: Christina Gigliotti, PhD 858-822-4800 (email@example.com)
Time involved: 1 visit
Description: This study will obtain a blood sample from persons with Alzheimer’s disease to make pluripotent stem cells that can be reprogrammed into nerve or other cells to study Alzheimer’s disease mechanisms
Requirements: Able to come in for one time appointment to have blood draw
Stem Cells Derived from Skin Fibroblasts PI: Douglas Galasko, MD Contact: Christina Gigliotti, PhD 858-822-4800 (firstname.lastname@example.org)
Time involved: one time only
Description: The purpose of this study is to study mechanisms of brain aging by deriving neurons from skin biopsies. A small piece of skin is removed from the forearm, the cells are gown in a dish, and induced to become neurons.
Requirements: Age 65 and older; Diagnosis of Alzheimer’s disease; study partner.
*can be scheduled in conjunction with CIRM study if interested in donating both blood and skin sample and participating in both protocols*
Clinical Drug Trials:
TRIAD: Avanir (AVP-786) PI: James Lohr, MD Contact: Lorraine Cheng, MA (858) 775-8869 (Locheng@ucsd.edu)
Time involved: 16 weeks
Description: The purpose of this study is to evaluate the efficacy, safety, and tolerability of deuterated [d6]-dextromethorphan hydrobromide/quinidine sulfate (d6-DM/Q or AVP-786) in persons with agitation secondary to dementia of the Alzheimer's type. AVP-786 is a combination product of d6-DM with quinidine sulfate (Q) that interacts with multiple receptors to decrease behavioral disturbances associated with AD.
Requirements: Age 50-90; MMSE 6-26; study partner, moderate to severe agitation/aggression
EMERGE: Biogen (BIIB037)
PI: James Lohr, MD Contact: Mallory Mulvaney, email@example.com
Time involved: 2 years
Description: The purpose of this study is to evaluate the efficacy and safety of Aducanumab (BIIB037) in persons with early Alzheimer's disease. Aducanumab is a human monoclonal antibody, and it is being evaluated to determine whether it can remove the amyloid plaques and slow the progression of symptoms in early AD.
Requirements: Age 50-85; MMSE 24-30; study partner, PET and MRI scans, able to have monthly infusions